Kynam Capital Management, LP Travere Therapeutics, Inc. Transaction History
Kynam Capital Management, LP
- $1.22 Billion
- Q3 2024
A detailed history of Kynam Capital Management, LP transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Kynam Capital Management, LP holds 1,371,511 shares of TVTX stock, worth $24.5 Million. This represents 1.57% of its overall portfolio holdings.
Number of Shares
1,371,511
Previous 2,021,659
32.16%
Holding current value
$24.5 Million
Previous $16.6 Million
15.46%
% of portfolio
1.57%
Previous 1.29%
Shares
11 transactions
Others Institutions Holding TVTX
# of Institutions
193Shares Held
84.6MCall Options Held
776KPut Options Held
900K-
Armistice Capital, LLC New York, NY7.65MShares$137 Million1.78% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$137 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.9MShares$123 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.68MShares$83.7 Million2.23% of portfolio
-
Woodline Partners LP San Francisco, CA4.34MShares$77.5 Million0.55% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.15B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...